Analyst Price Targets — RVMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 11:00 am | Eva Fortea Verdejo | Wells Fargo | $144.00 | $103.24 | StreetInsider | Revolution (RVMD) PT Raised to $144 at Wells Fargo |
| January 27, 2026 12:50 pm | Jay Olson | Oppenheimer | $150.00 | $97.78 | TheFly | Revolution Medicines price target raised to $150 from $75 at Oppenheimer |
| January 22, 2026 1:32 pm | — | UBS | $170.00 | $117.85 | TheFly | Revolution Medicines price target raised to $170 from $85 at Stifel |
| January 21, 2026 11:37 am | Leonid Timashev | RBC Capital | $140.00 | $116.22 | TheFly | Revolution Medicines price target raised to $140 from $77 at RBC Capital |
| January 20, 2026 12:19 pm | — | Guggenheim | $160.00 | $120.28 | TheFly | Revolution Medicines price target raised to $160 from $92 at Guggenheim |
| January 13, 2026 2:07 pm | Andrea Newkirk | Goldman Sachs | $73.00 | $119.95 | StreetInsider | Goldman Sachs on Revolution (RVMD): 'Catalyst-rich 2026 underpins the breadth of the clinical portfolio' |
| January 13, 2026 11:58 am | — | Mizuho Securities | $143.00 | $117.17 | TheFly | Revolution Medicines price target raised to $143 from $90 at Mizuho |
| January 9, 2026 1:38 pm | — | Wedbush | $147.00 | $112.68 | TheFly | Revolution Medicines price target raised to $147 from $80 at Wedbush |
| November 3, 2025 7:16 am | Leonid Timashev | RBC Capital | $77.00 | $58.84 | StreetInsider | RBC Capital Starts Revolution (RVMD) at Outperform |
| October 17, 2025 1:32 pm | Alex Stranahan | National Bank | $80.00 | $53.81 | TheFly | Revolution Medicines price target raised to $80 from $78 at BofA |
Latest News for RVMD
Revolution Medicines posts a wider-than-expected Q4 loss and sees 2026 operating expenses of $1.6B-$1.7B as it advances late-stage RAS pipeline studies.
Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter and full year ended December 31, 2025, and provided an update on corporate progress.
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in a fireside chat as part of the TD Cowen 46th Annual Health Care Conference on Tuesday,…
Raiffeisen Bank International AG acquired a new position in Revolution Medicines, Inc. (NASDAQ: RVMD) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 20,000 shares of the company's stock, valued at approximately $921,000. A number of other institutional investors and
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RVMD.
U.S. House Trading
No House trades found for RVMD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.